{"id":"multivalent-pneumococcal-vaccine-formulation-2","_chembl":null,"allNames":"multivalent pneumococcal vaccine - formulation 2","_dailymed":null,"mechanism":{"target":"","drugClass":"Pneumococcal vaccine","explanation":"The vaccine contains purified polysaccharides from various pneumococcal serotypes, which trigger the body to recognize and fight off these bacteria, reducing the risk of infections such as pneumonia and meningitis.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against multiple strains of Streptococcus pneumoniae, enhancing protection against pneumococcal diseases."},"_scrapedAt":"2026-03-28T04:11:37.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:56:30.121275+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT06182124","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-12-20","conditions":"Pneumococcal Disease","enrollment":558},{"nctId":"NCT03642847","phase":"PHASE1","title":"Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-08-29","conditions":"Pneumococcal Infections","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Multivalent Pneumococcal Vaccine - Formulation 2","genericName":"multivalent-pneumococcal-vaccine-formulation-2","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","aiSummary":"Multivalent Pneumococcal Vaccine - Formulation 2 is being studied for its safety and immune response in adults, specifically for the prevention of pneumococcal disease and infections. The vaccine is part of a Phase 1/2 clinical trial, which also includes a comparison with the 20-valent pneumococcal conjugate vaccine (20vPnC) and Multivalent Pneumococcal Vaccine - Formulation 1.","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:56:30.121275+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}